A Study in Healthy Men to Compare Two Different Oral Formulations of BI 1810631 and to Test How Food or Rabeprazole Influence the Amount of BI 1810631 in the Blood

Model scores of the 29,894 trials active now.

Model score 4% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 5% of the time (4,470 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2022-09-13. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: bimultipleprdosesclinical relevance
  Phrases that lowered it: healthyformulationbloodthe pharmacokineticsadministration
• Design: crossover (lowers risk) · Design
• Phase: 1 (lowers risk) · Design
• Sponsor's past termination rate: 8.4% (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 12.9% (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 99 (lowers risk) · Sponsor's track record
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Has a data monitoring committee: No (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor's past trials: 694 (raises risk) · Sponsor's track record
• Blinding: none (lowers risk) · Design
• Drug's FAERS reports marked serious: 85.2% (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Maximum age: 45 (lowers risk) · Who can join
• Number of arms: 4 (lowers risk) · Design
• Drug's FAERS reports before start: 37875 (lowers risk) · Drug's FDA history
• Disease area, neurology: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study in Healthy Men to Test How Zongertinib is Taken up in the Body When Taken With or Without Food NCT06075277 · started 2023 · scored riskier than 4% of active trials completed
• A Study in Healthy Men to Test How Zongertinib (BI 1810631) is Taken up and Processed by the Body NCT05879991 · started 2023 · scored riskier than 7% of active trials completed
• A Study in Healthy Men to Test How Different Doses of BI 1815368 Are Tolerated and How BI 1815368 is Taken up in the Body With or Without Food NCT05337592 · started 2022 · scored riskier than 8% of active trials completed
• A Study to Test How BI 1819479 is Taken up and Processed by the Body NCT07065617 · started 2025 · scored riskier than 6% of active trials terminated
• A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated and Taken up by the Body With or Without Food NCT04801693 · started 2021 · scored riskier than 21% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.